Conceptio
›
Archive
›
Europe PMC
Europe PMC
open access
Adonertinib (FHND9041) versus Afatinib as First-line Treatment for Advanced Non-small-cell Lung Cancer with EGFR Sensitive Mutation (FHND9041-Ⅲ-01): A Multi-centre, Open-label, Randomised Phase 3 Trial
Shi Y et al.
Europe PMC · Papers · License: Open Access
Open Source ↗
biomedical, life science
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Automated hippocampal sclerosis detection, using AID-HS, shows robust performance across multi-centre paired 7T and 3T MRI
#658776
Evaluation of risk stratification at presentation using the Alinity high-sensitivity cardiac troponin I assay
#658777
A multimodal investigation of perceptual awareness in Alzheimer's disease
#658778
The timeline of brain aging in major depression: A prospective study from before first-onset to established illness
#658779
Mapping the Health Burden of Neighbourhood Deprivation: Neurobiological Evidence Across the Life Span
#658780
Record
· ID 414785
Retrieved via
Conceptio
— every document is proof-bundled with source, license, and retrieval metadata.